About MediciNova, Inc
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California. Address: 4275 Executive Square, La Jolla, CA, United States, 92037
MediciNova, Inc News and around…
Latest news about MediciNova, Inc (MNOV) common stock and company :
LA JOLLA, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an abstract entitled “Improvement of Intracellular Lipid Metabolism by Tipelukast in the Pathogenesis of NASH/NAFLD" has been selected for poster presentation at The Liver Meeting® 2021, the annual meeting of the American Association for the Study of Liver Diseases
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
If you love investing in stocks you're bound to buy some losers. But the last three years have been particularly tough...
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Preclinical Studies for BARDA Contract Underway In June 2021, MediciNova, Inc. (NASDAQ:MNOV) announced it initiated a sheep study and also reached an agreement to conduct a mouse study as part of its partnership with the Biomedical Advanced Research and Development Authority (BARDA). The partnership is set up to
Friday morning, 94 companies reached new 52-week lows. Significant Points: Wix.com (NASDAQ:WIX) is the ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Gainers Exicure (NASDAQ:XCUR) stock moved upwards by 35.55% to $1.83 during Monday's pre-market session. The ...
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock moved upwards by 36.87% to $3.86 during Tuesday's pre-market ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $274.05 per unit.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
Gainers Odonate Therapeutics, Inc. (NASDAQ: ODT) shares rose 38.3% to $4.80 in pre-market trading following 13G from Ikarian ...
MediciNova Inc(NASDAQ: MNOV)will conduct a mouse studyto investigate the efficacy of MN-166 (ibudilast) in a murine ...
These three biotech stocks recently had positive news coming out of phase 2 trials, making them good choices for growth-oriented investors.
MediciNov Inc(NASDAQ: MNOV) sees a trading volume of 18.5 million shares after Zacks Small Cap Research increased the stock ...
Gainers Anavex Life Sciences (NASDAQ:AVXL) stock increased by 17.07% to $25.92 during Tuesday's regular session. As ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We're taking a look at the biggest pre-market stock movers for Tuesday as the perfect way to start the day. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner
Gainers Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) rose 29.2% to $3.71 in pre-market trading as traders circulated an article ...
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Positive Results for MN-166 in Phase 2 AUD Trial On June 21, 2021, MediciNova, Inc. (NASDAQ:MNOV) announced that positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) were published in Translational Psychiatry , a Nature publication ( Grodin et al., 2021 ). The trial was a
MediciNova, Inc (MNOV) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
